Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of open-label sacubitril/valsartan after acute myocardial infarction (PARADISE-MI extension)
2020-003906-29Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sacubitril + valsartan in myocardial infarction (MI), left ventricular dysfunction and pulmonary edema, sponsored by Novartis. Started Dec 2020; status: terminated.
02
Drugs
sacubitril + valsartan
03
Conditions
myocardial infarction (MI)left ventricular dysfunctionpulmonary edema
Beyond the preview
Go deeper on 2020-003906-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003906-29.